Tolero Pharmaceuticals to Present Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Relapsed Refractory MCL-1 dependent AML at EHA 2018

May 18, 2018 SALT LAKE CITY, May 18, 2018 /PRNewswire/ — Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the presentation of preliminary data from Zella201, an ongoing Phase 2 study evaluating the